<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1003" relname="span">Pancreatic cancer</segment>
<segment id="3" parent="2" relname="elaboration">( PC )</segment>
<segment id="4" parent="1002" relname="same_unit">is the one of the most aggressive and therapeutically ineffective malignant cancers .</segment>
<segment id="5" parent="1004" relname="joint">Mortality due to PC is fourth among the various cancer types worldwide .</segment>
<segment id="6" parent="1004" relname="joint">In 2018 , 458,918 new cases and 432,242 deaths by PC were recorded worldwide .</segment>
<segment id="7" parent="1007" relname="span">One of the primary reasons for the high mortality is the difficulty in early diagnosis of the disease</segment>
<segment id="8" parent="1008" relname="joint">because pancreas is behind the stomach</segment>
<segment id="9" parent="1008" relname="joint">and the patient shows general symptoms such as digestive problems , abdominal pain , and weight loss before metastasis .</segment>
<segment id="10" parent="1004" relname="joint">More than 80 % of PC patients show metastasis at the time of diagnosis .</segment>
<segment id="11" parent="1012" relname="concession">Despite various therapeutic methods ,</segment>
<segment id="12" parent="1012" relname="joint">the 5-year survival rate of PC is only 8 %</segment>
<segment id="13" parent="1012" relname="joint">and PC is projected to be the second leading cause of cancer deaths by 2030 .</segment>
<segment id="14" parent="1015" relname="span">Gemcitabine</segment>
<segment id="15" parent="14" relname="restatement">( Gem )</segment>
<segment id="16" parent="1014" relname="same_unit">is approved as a first-line chemotherapeutic drug for PC treatment .</segment>
<segment id="17" parent="1004" relname="joint">However , the response rate of Gem in PC patients is only 12 %</segment>
<segment id="18" parent="1004" relname="joint">and most patients are resistant to Gem within a few weeks .</segment>
<segment id="19" parent="1020" relname="joint">Less than 25 % of PC patients benefit from Gem treatment</segment>
<segment id="20" parent="1020" relname="joint">and the median overall survival is only 6 months .</segment>
<segment id="21" parent="1022" relname="span">In order to overcome these limitations of Gem , combinatorial regimens such as folinic acid , 5-fluorouracil , irinotecan and oxaliplatin</segment>
<segment id="22" parent="21" relname="restatement">( FOLFIRINOX )</segment>
<segment id="23" parent="1023" relname="span">have been widely used</segment>
<segment id="24" parent="23" relname="purpose">to treat PC patients .</segment>
<segment id="25" parent="1004" relname="joint">FOLFIRINOX presents higher response rates</segment>
<segment id="26" parent="1004" relname="joint">and its median overall survival is nearly 12 months .</segment>
<segment id="27" parent="1027" relname="span">However , this regimen shows considerable adverse effects</segment>
<segment id="28" parent="27" relname="elaboration">such as lower blood counts , fever , infection , diarrhea , and weight loss .</segment>
<segment id="29" parent="1030" relname="span">Therefore , development of new chemotherapeutic drugs</segment>
<segment id="30" parent="29" relname="elaboration">that can overcome chemoresistance</segment>
<segment id="31" parent="1004" relname="joint">and have less adverse effects on patients is needed .</segment>
<segment id="32" parent="1033" relname="span">Oat</segment>
<segment id="33" parent="32" relname="elaboration">( Avena sativa L. )</segment>
<segment id="34" parent="1034" relname="span">is an important cereal crop of the family of Poaceae</segment>
<segment id="35" parent="34" relname="elaboration">grown worldwide .</segment>
<segment id="36" parent="1037" relname="span">Oats have various advantages ;</segment>
<segment id="37" parent="1038" relname="span">they require less nutrients</segment>
<segment id="38" parent="37" relname="elaboration">to grow than the wheat or the corn .</segment>
<segment id="39" parent="1039" relname="same_unit">Additionally ,</segment>
<segment id="40" parent="41" relname="attribution">as people become more aware of their health ,</segment>
<segment id="41" parent="1040" relname="span">more people are consuming oats in the form of oatmeal , granola bars , cookies , and beverages .</segment>
<segment id="42" parent="43" relname="attribution">Recent studies have revealed</segment>
<segment id="43" parent="1042" relname="span">that oats possess beneficial health effects on aging , oxidant , cancer , liver injury , hypercholesterolemia , and gastrointestinal problems .</segment>
<segment id="44" parent="1045" relname="span">In this study , the effects of ethanol extract from the oat bran</segment>
<segment id="45" parent="44" relname="restatement">( OBE )</segment>
<segment id="46" parent="1044" relname="same_unit">on PC were investigated in vitro .</segment>
<segment id="47" parent="1046" relname="joint">To confirm the anti-cancer effect of OBE on PC cell viability , colony formation , cell cycle distribution , apoptosis , and proteins were evaluated .</segment>
<segment id="48" parent="1047" relname="span">Moreover , the combination effects of Gem and OBE on PC cells with acquired resistance to Gem was investigated</segment>
<segment id="49" parent="1048" relname="span">to test</segment>
<segment id="50" parent="51" relname="condition">if combination therapy could overcome drug resistance</segment>
<segment id="51" parent="1049" relname="span">developed during cancer treatment .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1004" relname="preparation"/>
<group id="1003" type="span" parent="1002" relname="same_unit"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1004" relname="joint"/>
<group id="1008" type="multinuc" parent="7" relname="cause"/>
<group id="1011" type="span" parent="1004" relname="joint"/>
<group id="1012" type="multinuc" parent="1011" relname="span"/>
<group id="1014" type="multinuc" parent="1004" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1019" type="span" parent="1004" relname="joint"/>
<group id="1020" type="multinuc" parent="1019" relname="span"/>
<group id="1021" type="multinuc" parent="1020" relname="purpose"/>
<group id="1022" type="span" parent="1021" relname="same_unit"/>
<group id="1023" type="span" parent="1021" relname="same_unit"/>
<group id="1027" type="span" parent="1004" relname="joint"/>
<group id="1030" type="span" parent="1004" relname="joint"/>
<group id="1032" type="multinuc" parent="1004" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="same_unit"/>
<group id="1034" type="span" parent="1032" relname="same_unit"/>
<group id="1036" type="span" parent="1004" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="span"/>
<group id="1038" type="span" parent="36" relname="elaboration"/>
<group id="1039" type="multinuc" parent="1037" relname="elaboration"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1042" type="span" parent="1004" relname="joint"/>
<group id="1043" type="span" parent="1004" relname="joint"/>
<group id="1044" type="multinuc" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1044" relname="same_unit"/>
<group id="1046" type="multinuc" parent="1044" relname="purpose"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1048" type="span" parent="48" relname="purpose"/>
<group id="1049" type="span" parent="49" relname="elaboration"/>
	</body>
</rst>
